1-12 of 12
Allison Pike
Close
Sort by
Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Abhishek Maiti, Courtney D. DiNardo, Maro Ohanian, Naval Daver, Gautam Borthakur, Kelly S. Chien, Ghayas C. Issa, Koichi Takahashi, Lucia Masarova, Yesid Alvarado Valero, Elias Jabbour, William G. Wierda, Nicholas J. Short, Melissa MacFarland, Allison Pike, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Marina Y. Konopleva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4289.
https://doi.org/10.1182/blood-2023-182901
Published: 2023
Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Ghayas C. Issa, Branko Cuglievan, Courtney D. DiNardo, Nicholas J. Short, David McCall, Amber Gibson, Cesar Nunez, Miriam B. Garcia, Michael Roth, Aram Bidikian, Allison Pike, Sheila Tan, Brianna Kammerer, Musa Yilmaz, Tapan M. Kadia, Naveen Pemmaraju, Maro Ohanian, Naval Daver, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 58.
https://doi.org/10.1182/blood-2023-182337
Published: 2023
Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Musa Yilmaz, Muharrem Muftuoglu, Courtney D. DiNardo, Tapan M. Kadia, Marina Y. Konopleva, Gautam Borthakur, Naveen Pemmaraju, Nicholas J. Short, Yesid Alvarado Valero, Abhishek Maiti, Lucia Masarova, Guillermo Montalban-Bravo, Carissa Jurisprudencia, Allison Pike, Sanam Loghavi, Keyur P. Patel, Guilin Tang, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Naval Daver
Journal: Blood
Blood (2023) 142 (Supplement 1): 158.
https://doi.org/10.1182/blood-2023-186699
Published: 2023
Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5906.
https://doi.org/10.1182/blood-2019-127272
Published: 2019
Journal Articles

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, Philip A. Thompson, MBBS, Gautam Borthakur, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Elias J. Jabbour, MD, Marina Y. Konopleva, MD PhD, Koichi Takahashi, MD, Steven M. Kornblau, MD, Courtney D. DiNardo, MDMSc, Zeev E. Estrov, MD, Wilmer Flores, Sreyashi Basu, PhD, James P Allison, PhD, Padmanee Sharma, MD PhD, Sherry A. Pierce, BSN, BA, Allison Pike, RN, Jorge E. Cortes, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 905.
https://doi.org/10.1182/blood-2018-99-116078
Published: 2018
Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 255.
https://doi.org/10.1182/blood.V130.Suppl_1.255.255
Published: 2017
Journal Articles

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Farhad Ravandi, MBBS, Naval Daver, MD, Guillermo Garcia-Manero, MD, Christopher B Benton, MD, Philip A Thompson, MBBS, Gautam Borthakur, MD, Tapan Kadia, MD, Prajwal C Boddu, MD, Yesid Alvarado, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD, Koichi Takahashi, MD, Steven Kornblau, MD, Courtney D. DiNardo, MDMSc, Zeev Estrov, MD, Wilmer Flores, Sreyashi Basu, James Allison, PhD, Padmanee Sharma, MD PhD, Sherry Pierce, Mark Brandt, Allison Pike, RN, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 815.
https://doi.org/10.1182/blood.V130.Suppl_1.815.815
Published: 2017
Journal Articles

Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Koichi Takahashi, MD, Christopher B. Benton, MD, Allison Pike, RN, Sherry Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 2817.
https://doi.org/10.1182/blood.V128.22.2817.2817
Published: 2016
Journal Articles

Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia

Nicholas J. Short, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Rita B. Khouri, Gautam Borthakur, MD, Nitin Jain, MD, Marina Konopleva, MD PhD, Zeev Estrov, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Courtney D DiNardo, MD, Susan M. O'Brien, MD, Syed Shah, Allison Pike, RN, Mark Brandt, BS, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD
Journal: Blood
Blood (2016) 128 (22): 1067.
https://doi.org/10.1182/blood.V128.22.1067.1067
Published: 2016
Journal Articles

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Elias J. Jabbour, MD, Allison Pike, RN, Kate J Newberry, PhD, Lingsha Zhou, Sherry Pierce, BSN, BA, Xuemei Wang, MS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 478.
https://doi.org/10.1182/blood.V128.22.478.478
Published: 2016
Journal Articles

Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial

Paul B. Koller, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jad Chahoud, MD, Allison Pike, RN, Mark Brandt, BS, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Elias Jabbour
Journal: Blood
Blood (2015) 126 (23): 2508.
https://doi.org/10.1182/blood.V126.23.2508.2508
Published: 2015
Journal Articles

Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Allison Pike, RN, Carol Bivins, RN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2014) 124 (21): 5283.
https://doi.org/10.1182/blood.V124.21.5283.5283
Published: 2014